Cognition Therapeutics, Inc. — Q3 2022 Form 10-Q
Reporting period: Three and nine months ended September 30, 2022. Cognition Therapeutics is a clinical-stage biopharmaceutical company developing CNS and retinal disease therapies, with CT1812 as its lead candidate. It reported no product-sales revenue; grant reimbursements are recorded as other income.
Key financial metrics
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Research and development expense | $8.3m | $3.7m | $23.9m | $13.0m |
| General and administrative expense | $4.4m | $1.5m | $10.4m | $3.8m |
| Total operating expenses | $12.6m | $5.2m | $34.3m | $16.8m |
| Grant income | $5.9m | $3.0m | $18.2m | $12.4m |
| Net loss | $6.6m | $3.1m | $16.2m | $4.4m |
| Operating cash used | Not presented quarterly | Not presented quarterly | $8.3m | $3.7m |
Balance sheet at September 30, 2022: Cash and cash equivalents were $46.6m; current assets $50.9m; current liabilities $12.1m; total liabilities $14.2m; and stockholders’ equity $39.3m. The company reported no outstanding balance on its insurance-premium financing loan at quarter-end. Operating lease liabilities were $0.7m. No product-revenue margin is meaningful because there were no product sales.
Material changes versus prior periods
- Q3 net loss widened by $3.5m year over year, while nine-month net loss increased by $11.8m.
- Nine-month R&D costs rose $10.9m, principally from increased Phase 2 clinical-trial activity and personnel costs; manufacturing expense fell $2.5m due to timing.
- Nine-month G&A costs rose $6.6m, reflecting higher professional fees, equity compensation, insurance, and staffing costs.
- Nine-month operating cash use increased $4.6m year over year. Cash declined $8.1m from year-end 2021 to $46.6m at September 30, 2022.
- Common shares outstanding increased from 22.23m at December 31, 2021 to 23.97m at September 30, 2022, largely reflecting option exercises.
Outlook, risks, and unusual items
- Management estimated that cash, the follow-on offering proceeds and grant income would fund operations into the first half of 2024. Separately, the financial-statement note said existing cash was expected to cover operating and capital needs for at least one year after the filing date. Both estimates depend on assumptions and spending needs.
- On November 10, 2022, after quarter-end, the company agreed to sell 5.0m shares at $1.20 per share, expecting approximately $5.4m net proceeds; closing was expected November 15, subject to conditions. Underwriters received an option for up to 750,000 additional shares.
- The company expects continuing losses and increasing expenses and will need additional funding beyond its stated runway. It may seek grants, equity or debt financing, collaborations, or licensing arrangements; financing may dilute shareholders or be unavailable on acceptable terms.
- Grant income is tied to eligible reimbursable costs, subject to award limits and government audit. Awarded grants had project periods extending through May 31, 2025, subject to extension.
- Key risks include clinical and regulatory uncertainty for CT1812, trial delays or disruption (including COVID-19), inflation and geopolitical instability, reliance on third-party manufacturers and research organizations, and dependence on future grants or capital raising. The company reported no contingency with at least a reasonable possibility of material loss and no material change to previously disclosed risk factors.
- No formal financial guidance was provided. Management stated it cannot predict when, or whether, the company will achieve profitability. Disclosure controls were assessed as effective, with no material change in internal control over financial reporting reported for the quarter.
Important facts for investors to verify
- Whether the follow-on offering closed as expected, the final net proceeds, and whether the underwriters exercised their additional-share option.
- The assumptions underlying the first-half 2024 runway estimate, including grant receipts, clinical-trial spending, and the timing of additional financing needs.
- CT1812 clinical-trial progress, costs, and milestones, as well as the timing and eligibility of grant reimbursements.
- The extent of future dilution from equity compensation, option exercises, and additional capital raises.